Literature DB >> 3252267

Do serotoninergic drugs decrease energy intake by reducing fat or carbohydrate intake? Effect of d-fenfluramine with supplemented weight-increasing diets.

J E Blundell1, A J Hill.   

Abstract

The capacity of serotoninergic drugs to selectively suppress carbohydrate (CHO) intake was investigated using a procedure sensitive to drug action. The drug d-fenfluramine was administered chronically to rats whose weight had been increased by exposure to either a fat or CHO-supplemented hyperphagia-inducing diet. The drug exerted a more potent anorexic effect and weight-reducing action in rats given the dietary supplements than in control chow-fed rats. Tolerance to the drug was not apparent even after 40 days of treatment. However, there was no evidence for a selective inhibition of CHO intake, nor was the drug more potent with the CHO-supplemented diet. d-Fenfluramine was equally effective against the hyperphagia and weight gain induced by either fat or CHO supplements.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252267     DOI: 10.1016/0091-3057(88)90382-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  5-HT manipulation and dietary choice: variable carbohydrate (Polycose) suppression demonstrated only under specific experimental conditions.

Authors:  C L Lawton; J E Blundell
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 2.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

3.  A comparison of the effects of d- and l-fenfluramine and d-amphetamine on energy and macronutrient intake in human subjects.

Authors:  E Goodall; S Feeney; J McGuirk; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 4.  Psychotropic drugs in the treatment of obesity: what promise?

Authors:  Jose C Appolinario; João R Bueno; Walmir Coutinho
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.